PRESS RELEASE
News
-
-
-
-
-
PRESS RELEASE
Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030 to develop a novel antisense oligonucleotide
Theranexus, Diverchim, and Inserm's ARNA laboratory receive €4.7 million funding from French Government to develop autophagy activation therapy for rare neurological diseases under the PickASO project in collaboration with France 2030 -
-
PRESS RELEASE
Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1
Theranexus and BBDF announce positive final results after 18-month Phase I/II trial of Batten-1 in juvenile Batten disease (CLN3) patients, showing stabilization of motor symptoms progression in young adults
